David Woodhouse
Directeur Général chez NGM BIOPHARMACEUTICALS, INC.
Postes actifs de David Woodhouse
Sociétés | Poste | Début | Fin |
---|---|---|---|
NGM BIOPHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/09/2018 | - |
Directeur Général | 01/09/2018 | - | |
Directeur Financier/CFO | 02/03/2015 | 13/07/2020 | |
SURROZEN, INC. | Independent Dir/Board Member | 01/09/2020 | - |
Président | - | - | |
Directeur/Membre du Conseil | 01/09/2020 | - | |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Directeur/Membre du Conseil | 25/09/2020 | - |
Historique de carrière de David Woodhouse
Anciens postes connus de David Woodhouse
Sociétés | Poste | Début | Fin |
---|---|---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | 01/01/2002 | 01/01/2015 |
AMGEN INC. | Corporate Officer/Principal | - | - |
Formation de David Woodhouse
Stanford University School of Medicine | Doctorate Degree |
Tuck School of Business at Dartmouth | Masters Business Admin |
University of California, Santa Barbara | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 9 |
Opérationnelle
Director/Board Member | 3 |
Corporate Officer/Principal | 2 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 4 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
NGM BIOPHARMACEUTICALS, INC. | Health Technology |
SURROZEN, INC. | Health Technology |
AMGEN INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- David Woodhouse
- Expérience